title: [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
abstract: PARP inhibitors are novel drugs under development in oncology, particularly against breast and ovarian cancer. They act on the DNA repair mechanisms in synergy with the loss of BRCA function of the tumor cells, thereby inducing a genetic instability that leads to cell death. The clinical benefit of PARP inhibitors has been demonstrated for breast and ovarian cancer in BRCA germline mutation carriers. Their use in sporadic triple negative breast cancers, that share similarities with BRCA1 mutated tumors, is currently investigated with encouraging preliminary results.
authors: Unité d'oncogynécologie médicale, Service d'oncologie médicale, Département des spécialités de médecine, HUG, 1211 Genève 14. ludivine.mercier-vogel@hcuge.ch
authors: L
authors: L
authors: Mercier-Vogel
authors: A
authors: A
authors: Bodmer
authors: M
authors: M
authors: Castiglione
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D019398:Genes, BRCA1 / Q000187:drug effects; D024522:Genes, BRCA2 / Q000187:drug effects; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors